Why CREST-2 Trial Results Should Inform, Not Replace, Clinical Judgment

Why It Matters

The findings shape how clinicians balance revascularization against medical therapy, influencing guideline updates and reimbursement decisions while underscoring the need for surgeon expertise in patient selection.

Key Takeaways

• CREST‑2 shows both CEA and TFCAS lower stroke risk
• No superiority of TFCAS over CEA demonstrated
• Trial used intensive medical management not typical in practice
• Real‑world VQI data still favor CEA outcomes

Pulse Analysis

Asymptomatic carotid stenosis remains a high‑stakes dilemma for vascular specialists, who must weigh the modest absolute stroke risk against the procedural hazards of revascularization. The CREST‑2 program, published in late 2025, refreshed this debate by delivering two rigorously blinded trials that paired intensive medical management with either carotid endarterectomy or transfemoral stenting. By achieving four‑year stroke rates under 4% for both interventions, the study confirms that modern medical therapy combined with revascularization can dramatically curb cerebrovascular events, a finding that resonates with the broader push toward precision stroke prevention.

Nevertheless, the trial’s architecture imposes critical limits on its interpretive power. Each arm enrolled distinct patient cohorts under highly selective criteria, and the stenting arm involved only high‑performing operators treating favorable lesions. This design precludes a head‑to‑head comparison, yet media coverage sometimes suggests TFCAS outperforms CEA. Moreover, the intensive medical regimen—stringent LDL targets, aggressive antihypertensive control, and close follow‑up—exceeds what most community practices can sustain. The omission of newer techniques such as transcarotid artery revascularization (TCAR) further narrows the study’s relevance to today’s procedural landscape.

For clinicians, the pragmatic takeaway is to integrate CREST‑2 insights with real‑world evidence from registries like the Vascular Quality Initiative, which consistently demonstrate lower peri‑operative stroke and death rates for endarterectomy performed by experienced vascular surgeons. Decision‑making should remain individualized, factoring lesion anatomy, patient comorbidities, and surgeon expertise rather than relying solely on trial averages. As guidelines evolve, the consensus will likely position CREST‑2 as a pivotal data point that reinforces, not replaces, the decades‑long body of evidence supporting surgical stewardship of carotid disease.